IMDX - Oncocyte Corp
3.56
-0.550 -15.449%
Share volume: 341,804
Last Updated: 03-27-2026
Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances:
-0.05%
PREVIOUS CLOSE
CHG
CHG%
$4.11
-0.55
-0.13%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-15-2024 | 08-08-2024 | 11-12-2024 | 03-24-2025 | 05-12-2025 | 08-11-2025 | 11-10-2025 | 03-26-2026 | |
| Assets | |||||||||
| Total Assets | 70.973 M | 74.720 M | 70.216 M | 35.081 M | 60.360 M | 50.517 M | 43.937 M | 25.756 M | |
| Current Assets | 6.535 M | 9.968 M | 4.793 M | 11.759 M | 36.263 M | 26.842 M | 21.389 M | 15.306 M | |
| Inventories | 0.000 | 0.000 | 232.000 K | 410.000 K | 459.000 K | 693.000 K | 471.000 K | 446.000 K | |
| Other Current Assets | 735.000 K | 32.000 K | 362.000 K | 279.000 K | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 735.000 K | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Receivables | 161.000 K | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 5.578 M | 9.256 M | 3.363 M | 8.636 M | 31.029 M | 24.287 M | 18.692 M | 11.583 M | |
| Total Non-current Assets | 64.438 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 3.528 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Assets | 2.637 M | 64.752 M | 65.423 M | 23.322 M | 24.097 M | 23.675 M | 22.548 M | 10.450 M | |
| Intangible Assets | 56.573 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 70.973 M | 74.720 M | 70.216 M | 35.081 M | 60.360 M | 50.517 M | 43.937 M | 25.756 M | |
| Total liabilities | 54.053 M | 52.017 M | 60.505 M | 47.355 M | 50.142 M | 49.419 M | 53.133 M | 57.220 M | |
| Total current liabilities | 8.327 M | 7.198 M | 9.090 M | 7.275 M | 9.683 M | 6.652 M | 7.660 M | 12.075 M | |
| Accounts Payable | 908.000 K | 1.430 M | 1.857 M | 2.697 M | 4.206 M | 1.848 M | 1.658 M | 3.483 M | |
| Other liabilities | 43.212 M | 42.181 M | 48.707 M | 37.711 M | 38.385 M | 40.933 M | 43.944 M | 43.455 M | |
| Current long term debt | 821.000 K | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 2.514 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 43.212 M | 42.181 M | 48.707 M | 37.711 M | 38.385 M | 40.933 M | 43.944 M | 43.455 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 16.920 M | 22.703 M | 9.711 M | -12.274 M | 10.218 M | 1.098 M | -9.196 M | -31.464 M | |
| Common stock | 8.264 M | 326.201 M | 326.682 M | 338.244 M | 367.387 M | 367.965 M | 368.524 M | 369.211 M | |
| Retained earnings | -299.005 M | -303.535 M | -317.028 M | -350.539 M | -357.210 M | -366.952 M | -377.806 M | -400.761 M |